|
健保碼及健保價 |
|
See related Fragmin inj[弗列明 注射劑] information |
|
|
|
製造商 |
Pfizer |
|
代理/經銷商 |
Arich |
|
成份 |
Dalteparin Na (low molecular wt heparin Na). |
|
適應症 |
Treatment of acute deep venous thrombosis. Prevention of clotting in the extracorporeal system during hemodialysis & hemofiltration. |
|
用量 |
General surgery with associated risk of thromboembolic complications 2,500 iu SC within 2 hr pre-op & thereafter each morning until patient is mobilised (generally 5-7 days or longer). General surgery associated with additional risk factors & orthopedic surgery Pre-op start: 5,000 iu SC the evening pre-op & 5,000 iu SC the following evenings until patient is mobilised. Alternatively, 2,500 iu SC within 2 hr pre-op & 2,500 iu SC 8-12 hr later, but no sooner than 4 hr after the end of surgery. 5,000 iu SC each morning on following days. Post-op start: 2500 iu SC 4-8 hr post-op, but no sooner than 4 hr after the end of surgery. 5,000 iu SC each morning on following days. Generally for 5-7 days or longer. Prophylaxis to patients with substantially increased risk of venous thromboembolism & that are temporarily immobilized due to acute illness such as cardiac/respiratory insufficiency, severe infections 5000 iu SC once daily for 12-14 days or longer in patients with restricted mobility. Treatment of acute deep venous thrombosis & pulmonary embolism & extended thromboprophylaxis in cancer patients 200 iu/kg SC once daily for 1st 30 days of treatment. Total daily dose: 18,000 iu daily. 150 iu/kg SC once daily for months 2-6. |
|
過量 |
View Fragmin[弗列明] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
禁忌 |
Confirmed or suspected history of immunologically-mediated heparin-induced thrombocytopenia. Active, clinically significant bleeding (eg. GI ulceration or bleeding or cerebral hemorrhage). Severe coagulation disorders, septic endocarditis. Recent injury to, or surgical procedures of, the CNS, eyes &/or ears. |
|
警告 |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Fragmin[弗列明] detailed prescribing infomation |
|
注意事項 |
click to view Fragmin[弗列明] detailed prescribing infomation |
|
不良反應 |
Reversible non-immunologically-mediated thrombocytopenia (type 1), transient elevation of liver transaminases, bleeding, hematoma at inj site, allergic reactions, pain at inj site.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
副作用 |
View Fragmin[弗列明] side effects |
|
交互作用 |
Anticoagulant effect may be enhanced by acetylsalicylic acid, NSAIDs, vit K antagonists & dextran.
View more drug interactions with Fragmin[弗列明] |
|
儲存 |
View Fragmin[弗列明] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Fragmin[弗列明] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Fragmin[弗列明] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Fragmin 注射劑 |
|
Fragmin (Pre-filled syringe) 2500 IU/0.2 mL x 10's |
 |
|
Fragmin (Ampoule) 2500 IU/1 mL x 4 mL x 1's |
|
Fragmin (Pre-filled syringe) 5000 IU/0.2 mL x 10's |
 |
|
|
|
Manufacturer: |
Pfizer |
|
Distributor: |
Arich |
|
|
|
|
|
